CCIA
SUPN icon

Campbell & Co Investment Adviser’s Supernus Pharmaceuticals SUPN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,151
Closed -$306K – 1406
2025
Q4 		$306K Buy
+6,151
New +$299K 0.01% 970
2024
Q4 		– Sell
-6,470
Closed -$202K – 1353
2024
Q3 		$202K Sell
6,470
-6,724
-51% -$210K 0.02% 1016
2024
Q2 		$353K Buy
+13,194
New +$382K 0.03% 774
2024
Q1 		– Sell
-26,210
Closed -$759K – 1356
2023
Q4 		$759K Buy
+26,210
New +$695K 0.07% 514
2022
Q4 		– Sell
-15,923
Closed -$539K – 993
2022
Q3 		$539K Buy
+15,923
New +$518K 0.12% 297
2021
Q1 		– Sell
-9,069
Closed -$228K – 598
2020
Q4 		$228K Sell
9,069
-2,300
-20% -$49.5K 0.14% 331
2020
Q3 		$237K Buy
11,369
+1,268
+13% +$28.8K 0.18% 264
2020
Q2 		$240K Buy
+10,101
New +$223K 0.3% 162
2019
Q2 		– Sell
-5,809
Closed -$204K – 699
2019
Q1 		$204K Buy
+5,809
New +$216K 0.1% 448
2016
Q4 		– Sell
-8,504
Closed -$210K – 191
2016
Q3 		$210K Buy
+8,504
New +$192K 0.57% 85

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's SUPN Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 6,151 shares — an estimated $306K sold.

Campbell & Co Investment Adviser first reported a position in SUPN in Q3 2016 and held it in 10 quarters. The position peaked at $759K in Q4 2023. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 6,151 Supernus Pharmaceuticals shares in Q1 2026, an estimated $306K.
  • Campbell & Co Investment Adviser first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 10 quarters.
  • Campbell & Co Investment Adviser's Supernus Pharmaceuticals position peaked at $759K in Q4 2023.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.